Drug reference

amphotericin b (liposomal)

Drug monograph

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Lipid formulations are preferentially taken up by reticuloendothelial tissues. This allows a large amount of drug to be delivered over a short period with less free drug available to cause toxicity.

Indications

Visceral Leishmaniasis (VL) (preferred in Bihar, India, and Mediterranean countries; preferred drug of choice globally)Visceral Leishmaniasis (VL) in HIV co-infection (drug of choice for primary treatment and relapses)Post-kala-azar dermal leishmaniasis (PKDL)Mucosal Leishmaniasis (ML)

Dosing

Adult: US: 3 mg/kg daily on days 1–5, 14, and 21 (total dose, 21 mg/kg). Asia: 10–15 mg/kg total dose. Africa: ~18 mg/kg total dose. Mediterranean/American regions: ≥20 mg/kg total dose. India: single dose of 10 mg/kg for VL elimination program. HIV/VL co-infection (Americas and Mediterranean): 40 mg/kg total dose, administered as 4 mg/kg on days 1–5, 10, 17, 24, 31, and 38.…
Max dose: Daily dose flexible (1–10 mg/kg).